The Effect of Anesthetic Methods on Gastrointestinal Motility

Sponsor
Bozyaka Training and Research Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05951686
Collaborator
(none)
60
1
2
16.5
3.6

Study Details

Study Description

Brief Summary

The goal of this randomized controlled single blinded study is to compare the effect of the type of anesthesia on gastrointestinal motility in patients scheduled for laparoscopic sleeve gastrectomy. The main question it aims to answer is how do inhalation anesthesia and total intravenous anesthesia effect the gastrointestinal peristalsis during anastomosis.

Participants will be American Society of Anesthesiology (ASA) physical status II and III, between 18- 60 ages.

Researchers will compare inhalation anesthesia where desflurane is used with total intravenous anesthesia to see if the gastrointestinal motility differs between the groups.

Condition or Disease Intervention/Treatment Phase
  • Drug: Desflurane
  • Drug: Remifentanil infusion
  • Other: Fresh gas
  • Drug: Propofol infusion
N/A

Detailed Description

Aim of this study is to evaluate the effect of two anesthetic methods on gastric motility during laparoscopic sleeve gastrectomy. Patients scheduled for laparoscopic sleeve gastrectomy with American Society of Anesthesiology (ASA) physical status II and III will enrolled into two groups. Computer based randomization will be used for the group selection. Patients will be monitored with standard monitorization (peripheral oxygen saturation, non-invasive blood pressure, 3-lead electrocardiography and patient state index (PSI)). Preoxygenation will be performed via a face mask with 6 L/min oxygen for 5 minutes. All patients will receive intravenous 2 mg/kg propofol, 0.25 mcg/kg/min remifentanil for anesthesia induction. Rocuronium bromide will be used intravenously with a dose of 0.6 mg/kg for muscle relaxation. Endotracheal intubation will be performed. In Group 1, inhalation anesthetic, desflurane and in Group 2, propofol infusion will be used with a 2 L/ min fresh gas flow as a mixture of 50 %- 50 % oxygen- medical air for maintenance of general anesthesia. Remifentanil infusion with a dose of 0.05-2 mcg/kg/min will be used in both groups during anesthesia maintenance. Anesthesia depth will be monitored with EEG monitorization where a score of 25-50 will be achieved in PSI . End-tidal carbon dioxide pressure will be kept between 35 and 45 mmHg. End-expiratory positive pressure will be set to 8 mmHg and intraabdominal pressure will be set to 12 mmHg. The surgeon will assess the gastric motility during anastomosis. The peristalsis during 1 minute period will be counted. 1 gram paracetamol and 1 mg/kg tramadol will be given intravenously for pain management. Sugammadex will be used for the reversal of neuromuscular blockade. Postoperative nause and vomiting, the time of first fart will be noted. Surgeon's satisfaction during anastomosis will be assessed with 5 points Likert Scale. Data will be statistically analyzed.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Other
Official Title:
The Effect of Two Different Anesthetic Methods on Gastrointestinal Motility in Patients Scheduled for Laparoscopic Sleeve Gastrectomy: a Prospective, Randomized, Single Blinded Clinical Trial
Actual Study Start Date :
Aug 15, 2022
Anticipated Primary Completion Date :
Aug 15, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Group inhalation

Patients will receive desflurane as an inhalation anesthetic and remifentanil infusion for general anesthesia maintenance during the surgery. The doses of desflurane and remifentanil will be adjusted according to the Patient State Index (PSI) where the goal score is 25-50.

Drug: Desflurane
In inhalation group, desflurane will be used for general anesthesia maintenance under the screening with Patient State Index (PSI) between a score of 25-50. Remifentanil infusion is used with desflurane with a dose of 0.05-2 mcg/ kg/ min according to PSI . Fresh gas flow is used 2 L/ min with a mixture of 50%- 50% oxygen and medical air in both groups.
Other Names:
  • suprane
  • Drug: Remifentanil infusion
    Remifentanil infusion will be used with a dose of 0.05-2 mcg/ kg/ min under the screening with Patient State Index (PSI) between a score of 25-50 in both groups.
    Other Names:
  • ultiva
  • Other: Fresh gas
    Fresh gas flow will be used 2 L/ min with a mixture of 50%- 50% oxygen and medical air in both groups.

    Active Comparator: Group tiva

    Patients will receive total intravenous anesthesia with an infusion of propofol and remifentanil for general anesthesia maintenance during the surgery. The infusion doses will be changed according to the Patient State Index (PSI) where the goal score is 25-50.

    Drug: Remifentanil infusion
    Remifentanil infusion will be used with a dose of 0.05-2 mcg/ kg/ min under the screening with Patient State Index (PSI) between a score of 25-50 in both groups.
    Other Names:
  • ultiva
  • Other: Fresh gas
    Fresh gas flow will be used 2 L/ min with a mixture of 50%- 50% oxygen and medical air in both groups.

    Drug: Propofol infusion
    Propofol infusion will be used for general anesthesia maintenance with a dose of under the screening of Patient State Index (PSI) between a score of 25-50 in group tiva.
    Other Names:
  • propofol 2%
  • Outcome Measures

    Primary Outcome Measures

    1. Gastrointestinal motility [during surgery]

      Gastrointestinal motility is the number of peristalsis during a one minute period. The surgeon will be asked to count the number of peristalsis during surgical anastomosis in a one minute period.

    Secondary Outcome Measures

    1. Fart [up to 24 hours after surgery]

      The time of first fart

    2. Nause and vomiting [up to 24 hours after surgery]

      Incidence of postoperative nause and vomiting

    3. Satisfaction of surgeon [during surgery]

      Ease of anastomosis and satisfaction of surgeon will be measured with 5 point Likert Scale as 1: very dissatisfied, 2:dissatisfied, 3: neither dissatisfied or satisfied, 4: satisfied, 5: very satisfied

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • 18-60 ages

    • ASA II-III

    • Patients scheduled for elective laparoscopic sleeve gastrectomy

    • Body mass index 35 kg m2 and over

    Exclusion Criteria:
    • Hepatic disease

    • Kidney disease

    • Congestive heart disease

    • Diabetes mellitus

    • Neurological deficit

    • Psychiatric disease

    • Pregnancy

    • Delayed gastric empting

    • Previous bariatric surgery

    • Patient's refusal

    • Open surgery

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Izmir Bozyaka Training and Research Hospital İzmir Bozyaka Turkey

    Sponsors and Collaborators

    • Bozyaka Training and Research Hospital

    Investigators

    • Principal Investigator: Halide H Şahinkaya, MD, Izmir Bozyaka Education and Research Hospital
    • Study Chair: Ahmet M Öztürk, MD, Izmir Bozyaka Education and Research Hospital
    • Study Chair: Çağlar Ayar, MD, Izmir Bozyaka Education and Research Hospital
    • Study Chair: Hüseyin Özkarakaş, MD, Izmir Bozyaka Education and Research Hospital
    • Study Chair: Bülent Çalık, Ass. Prof, Izmir Bozyaka Education and Research Hospital
    • Study Chair: Zeki T Tekgül, Ass. Prof., Izmir Bozyaka Education and Research Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Halide Hande Şahinkaya, MD, Anesthesiology Specialist, Bozyaka Training and Research Hospital
    ClinicalTrials.gov Identifier:
    NCT05951686
    Other Study ID Numbers:
    • HandeBariatric
    First Posted:
    Jul 19, 2023
    Last Update Posted:
    Jul 19, 2023
    Last Verified:
    Jul 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Halide Hande Şahinkaya, MD, Anesthesiology Specialist, Bozyaka Training and Research Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 19, 2023